FDA approves asthma indication for Dupixent® (dupilumab)

_______________________________________________________________________________________

To Receive daily job alerts, Enter your email address, and dont forget to verify the job alerts:

Delivered by FeedBurner

SanofiThe U.S. Food and Drug Administration has approved Dupixent® (dupilumab) as an add-on maintenance therapy in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid-dependent asthma.